These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 28245771

  • 21. Do the Natural Chemical Compounds Interact with the Same Targets of Current Pharmacotherapy for Weight Management?-A Review.
    Luo S, Lenon GB, Gill H, Yuen H, Yang AWH, Hung A, Nguyen LT.
    Curr Drug Targets; 2019; 20(4):399-411. PubMed ID: 30173643
    [Abstract] [Full Text] [Related]

  • 22. Recent advances in the pathophysiology and pharmacological treatment of obesity.
    Chugh PK, Sharma S.
    J Clin Pharm Ther; 2012 Oct; 37(5):525-35. PubMed ID: 22462645
    [Abstract] [Full Text] [Related]

  • 23. Pharmacotherapy for the management of obesity.
    Patel D.
    Metabolism; 2015 Nov; 64(11):1376-85. PubMed ID: 26342499
    [Abstract] [Full Text] [Related]

  • 24. Anti-obesity drugs: a review about their effects and their safety.
    Derosa G, Maffioli P.
    Expert Opin Drug Saf; 2012 May; 11(3):459-71. PubMed ID: 22439841
    [Abstract] [Full Text] [Related]

  • 25. Medical treatment of obesity: the past, the present and the future.
    Bray GA.
    Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):665-84. PubMed ID: 25194183
    [Abstract] [Full Text] [Related]

  • 26. [Drug treatment of obesity--current situation and perspectives].
    Hainer V.
    Cas Lek Cesk; 2010 Aug; 149(11):513-9. PubMed ID: 21391349
    [Abstract] [Full Text] [Related]

  • 27. Past, Present, and Future of Pharmacologic Therapy in Obesity.
    Rodríguez JE, Campbell KM.
    Prim Care; 2016 Mar; 43(1):61-7, viii. PubMed ID: 26896200
    [Abstract] [Full Text] [Related]

  • 28. Pharmacotherapy for Obesity.
    Saunders KH, Shukla AP, Igel LI, Kumar RB, Aronne LJ.
    Endocrinol Metab Clin North Am; 2016 Sep; 45(3):521-38. PubMed ID: 27519128
    [Abstract] [Full Text] [Related]

  • 29. Obesity: Current Treatment and Future Horizons.
    Omran Z.
    Mini Rev Med Chem; 2017 Sep; 17(1):51-61. PubMed ID: 27320641
    [Abstract] [Full Text] [Related]

  • 30. Obesity: new perspectives and pharmacotherapies.
    Palamara KL, Mogul HR, Peterson SJ, Frishman WH.
    Cardiol Rev; 2006 Sep; 14(5):238-58. PubMed ID: 16924165
    [Abstract] [Full Text] [Related]

  • 31. Combination therapy for obesity.
    Wilding JP.
    J Psychopharmacol; 2017 Nov; 31(11):1503-1508. PubMed ID: 29132230
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. New medications for treatment of obesity: metabolic and cardiovascular effects.
    Pucci A, Finer N.
    Can J Cardiol; 2015 Feb; 31(2):142-52. PubMed ID: 25661549
    [Abstract] [Full Text] [Related]

  • 35. Update on obesity pharmacotherapy.
    Bray GA, Ryan DH.
    Ann N Y Acad Sci; 2014 Apr; 1311():1-13. PubMed ID: 24641701
    [Abstract] [Full Text] [Related]

  • 36. It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development.
    Chan JL, Roth JD, Weyer C.
    J Investig Med; 2009 Oct; 57(7):777-83. PubMed ID: 20029268
    [Abstract] [Full Text] [Related]

  • 37. Novel anti-obesity drugs.
    Proietto J, Fam BC, Ainslie DA, Thorburn AW.
    Expert Opin Investig Drugs; 2000 Jun; 9(6):1317-26. PubMed ID: 11060745
    [Abstract] [Full Text] [Related]

  • 38. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
    Halpern B, Mancini MC.
    Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
    [Abstract] [Full Text] [Related]

  • 39. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.
    Krentz AJ, Fujioka K, Hompesch M.
    Diabetes Obes Metab; 2016 Jun; 18(6):558-70. PubMed ID: 26936802
    [Abstract] [Full Text] [Related]

  • 40. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL, Bello NT.
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.